We feel like a lame duck on the markets.
Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer.
Discount: 37%
Average yearly return: 100%
TOP performer
On August 4, 2017: Exelixis reported:
- Most of the second quarter's revenue came from the $80.9 million in sales of Cabometyx, which was 30% higher than in the first quarter of the year.
- Thyroid cancer drug Cometriq, which has the same active ingredient as Cabometyx, contributed another $7.1 million.
- The Cabosun clinical trial data, testing Cabometyx as first-line therapy for patients with advanced kidney cancer, was confirmed.
- Exelixis paid off its remaining debt of $124 million, and is now debt-free.
No comments:
Post a Comment